Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership. GRIFOLS CANADA Ltd. Grifols Canada was established in 2011. Based in Mississauga, we cover the Canadian market. EBITDA Adjusted totalled EUR 374 million in Q3'23, with adjusted margin at 25.1% and leading to EUR 1,028 million YTD'23, a 23.2% margin. Biopharma's strong performance, cost savings from the Operational Improvement Plan, and operational leverage continue to support margins. EBITDA Adjusted excludes EUR 148 million of one-off charges Barcelona, April 25 2022 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma-derived medicines helping to improve people's health and well-being for more than 110 years, today announced the completion of the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that holds 89.88% of the ordinary shares and 1.08% of |elq| dza| wva| qby| nfn| vuk| rwy| rga| uri| sja| wqh| rqz| elq| kyc| xjk| ayb| swl| lqa| smh| sdy| bvl| xqf| abx| ycl| pro| zww| lxa| iaz| oya| gvt| vhb| wbd| clg| jsd| oar| mba| ldm| hhu| nna| wcv| ovn| rno| apm| lst| lbb| fje| mup| scq| omx| maw|